Patient-centered results from a multicenter study of continuous peripheral nerve blocks and postamputation phantom and residual limb pain: secondary outcomes from a randomized, clinical trial
Open Access
- 9 March 2023
- journal article
- research article
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 48 (9) , 471-477
Abstract
Introduction: We previously reported that a 6-day continuous peripheral nerve block reduces established postamputation phantom pain. To provide patients and providers with the information to best inform treatment decisions, here we reanalyze the data and present the results in a more patient-centered format. We also provide information on patient-defined clinically relevant benefits to facilitate evaluation of available studies and guide future trial design.Methods: The original trial enrolled participants with a limb amputation and phantom pain who were randomized to receive a 6-day continuous peripheral nerve block(s) of either ropivacaine (n=71) or saline (n=73) in a double-masked fashion. Here we calculate the percentage of each treatment group that experienced a clinically relevant improvement as defined by previous studies as well as present what the participants of our study defined as small, medium, and large analgesic improvements using the 7-point ordinal Patient Global Impression of Change scale.Results: Among patients who were given a 6-day ropivacaine infusion, 57% experienced at least a 2-point improvement on the 11-point numeric rating scale in their average and worst phantom pain 4 weeks postbaseline as compared with 26% (p=0.008). For all patients combined, the median (IQR) phantom pain Numeric Rating Scale improvements at 4 weeks considered small, medium, and large were 2 (0–2), 3 (2–5), and 5 (3–7), respectively. The median improvements in the Brief Pain Inventory interference subscale (0–70) associated with small, medium, and large analgesic changes were 8 (1–18), 22 (14–31), and 39 (26–47).Conclusions: Among patients with postamputation phantom pain, a continuous peripheral nerve block more than doubles the chance of a clinically relevant improvement in pain intensity. Amputees with phantom and/or residual limb pain rate analgesic improvements as clinically relevant similarly to other chronic pain etiologies, although their smallest relevant improvement in the Brief Pain Inventory was significantly larger than previously published values.Trial registration number: NCT01824082.Keywords
Funding Information
- Department of Defense Congressionally Directed Medical Research Program (DM120032, W81XWH-13-2-0009)
- National Institutes of Health (UL1TR001442)
This publication has 20 references indexed in Scilit:
- The PCORI Perspective on Patient-Centered Outcomes ResearchJAMA, 2014
- The Patient-Centered Outcomes Research Institute — Promoting Better Information, Decisions, and HealthNew England Journal of Medicine, 2011
- Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendationsPain, 2010
- Preventing Chronic Postsurgical PainAnesthesiology, 2010
- Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendationsPain, 2009
- Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT RecommendationsThe Journal of Pain, 2008
- Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendationsPain, 2006
- Why are so few randomized trials useful, and what can we do about it?Journal of Clinical Epidemiology, 2006
- EGGS for patient-centered outcomesInternational Urogynecology Journal, 2005
- Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain, 2001